Advertisement
Screener

CLIMB BIO, INC. (CLYM) Price / Book

2.8 / 5 stars · 68/120 Roast Me

Climb Bio, Inc. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

  • Climb Bio, Inc. price/book ratio for the quarter ending 2026-06-30 was 3.13, a 595.61% increase year-over-year.
  • Climb Bio, Inc. price/book ratio for the quarter ending 2026-03-31 was 2.21, a 417.56% increase year-over-year.
  • Climb Bio, Inc. price/book ratio for the quarter ending 2025-12-31 was 1.19, a 108.39% increase year-over-year.
  • Climb Bio, Inc. price/book ratio for the quarter ending 2025-09-30 was 0.78, a 50.25% decline year-over-year.
  • Climb Bio, Inc. price/book ratio for fiscal 2026 was 3.13.
  • Climb Bio, Inc. price/book ratio for fiscal 2025 was 1.19, a 108.39% increase from fiscal 2024.
  • Climb Bio, Inc. price/book ratio for fiscal 2024 was 0.57, a 17.80% decline from fiscal 2023.
  • Climb Bio, Inc. price/book ratio for fiscal 2023 was 0.7, a 8.24% decline from fiscal 2022.
Available history
2021-09-30 to 2026-06-30
Data captured

Historical Price/Book Ratio

DatePrice/Book RatioMarket capitalizationShareholder equity
2026-06-303.13$750.69M$239.55M
2026-03-312.21$326.74M$148.09M
2025-12-311.19$191.07M$160.48M
2025-09-300.78$137.73M$177M
2025-06-300.45$83.69M$185.76M
2025-03-310.43$82.44M$193.39M
2024-12-310.57$121.06M$211.88M
2024-09-301.56$342.17M$218.78M
2024-06-302.14$474.84M$222.28M
2024-03-310.71$75.96M$106.38M
2023-12-310.7$74.79M$107.6M
2023-09-300.66$72.24M$109.74M
2023-06-300.67$75.59M$112.5M
2023-03-310.67$78.22M$116.86M
2022-12-310.76$97.5M$128.72M
2022-09-300.64$85.81M$134.36M
2022-06-300.56$80.23M$142.24M
2022-03-311.44$222.9M$155.14M
2021-12-311.66$277.9M$167.2M
2021-09-302.67$471.06M$176.66M

Annual Price/Book Ratio

DatePrice/Book RatioMarket capitalizationShareholder equity
2026-06-303.13$750.69M$239.55M
2025-12-311.19$191.07M$160.48M
2024-12-310.57$121.06M$211.88M
2023-12-310.7$74.79M$107.6M
2022-12-310.76$97.5M$128.72M
2021-12-311.66$277.9M$167.2M

Similar stocks

Stock NameCountryMarket CapPE Ratio
IRONWOOD PHARMACEUTICALS INC (IRWD)United States$0.694B5.37
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
Nuvectis Pharma, Inc. (NVCT)United States$0.705B-17.53
Verastem, Inc. (VSTM)United States$0.706B-1.71
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
COLLEGIUM PHARMACEUTICAL, INC (COLL)United States$0.737B24.57
Neurogene Inc. (NGNE)$0.625B-4.46
Faeth Therapeutics, Inc. (FTH)United States$0.750B
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47